NCT06005818View on ClinicalTrials.gov

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

September 30, 2028

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Pembrolizumab injection

PD-1 antibody

Trial Locations (1)

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors

lead

University of Alabama at Birmingham

OTHER